1h - nmr spectra were recorded at 400 mhz and the chemical shifts are expressed in ppm relative to tetramethylsilane . the following abbreviations are used to describe the multiplicities of the signals : s ( singlet ), d ( doublet ), t ( triplet ), q ( quartet ), m ( multiplet ), dd ( doublet of doublets ), ddd ( doublet of doublet of doublets ), dt ( doublet of triplets ) and b ( broad ). biotage refers to prepacked silica gel cartridges containing kp - sil run on flash 12i chromatography module . lcms was conducted on a supelcosil lcabz + plus column ( 3 . 3 cm × 4 . 6 mm id ) eluting with 0 . 1 % hco 2 h and 0 . 01 m ammonium acetate in water ( solvent a ), and 0 . 05 % hco 2 h 5 % water in acetonitrile ( solvent b ), using the following elution gradient 0 - 0 . 7 min 0 % b , 0 . 7 - 4 . 2 min 100 % b , 4 . 2 - 5 . 3 min 0 % b , 5 . 3 - 5 . 5 min 0 % b at a flow rate of 3 ml / min . the mass spectra were recorded on a fisons vg platform spectrometer using electrospray positive and negative mode ( es + ve and es − ve ). dsc and tga profiles were obtained using a netzsch sta449c simultaneous thermal analyser using an unsealed pan with nitrogen gas flow and a thermal gradient of 10 ° c ./ min . the moisture sorption characteristics were obtained using a hiden lgasorb water sorption microbalance . the programme provides for stepwise increase in relative humidity ( rh ) from 0 to 90 % rh and then decrease back to 0 % rh in steps of 10 % rh . the xrpd analysis shown in fig1 and 2 were performed on a phillips x &# 39 ; pert mpd powder diffractometer , serial number dy667 . the method runs from 2 to 45 degrees 2theta with 0 . 02 degree 2theta step size and a 1 second collection time at each step . the xrpd analysis shown in fig4 employed the same instrument with an anton parr ttk thermal accessory using a method running from 2 to 35 degrees 2theta with 0 . 04 degree 2theta step size and a 1 second collection time . a solution of 6α , 9α - difluoro - 11β , 17α - dihydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid ( prepared in accordance with the procedure described in gb 2088877b ) ( 18 g , 43 . 64 mmol ) in anhydrous dichloromethane ( 200 ml ) and triethylamine ( 15 . 94 ml , 114 mmol ) was treated at & lt ; 5 ° c . with a solution of 2 - furoyl chloride ( 11 . 24 ml , 114 mmol ) in anhydrous dichloromethane ( 100 ml ) over approximately 40 min . the solution was stirred at & lt ; 5 ° c . for 30 min . the resulting solid was collected by filtration , washed successively with 3 . 5 % aqueous sodium hydrogen carbonate solution , water , 1m hydrochloric acid , and water and dried in vacuo at 60 ° c . to give a cream coloured solid . the dichloromethane filtrate was washed successively with 3 . 5 % sodium hydrogen carbonate solution , water , 1m hydrochloric acid , water , dried ( na 2 so 4 ) and evaporated to give a cream coloured solid which was combined with that isolated above . the combined solids ( 26 . 9 g ) were suspended in acetone ( 450 ml ) and stirred . diethylamine ( 16 . 8 ml , 162 mmol ) was added and the mixture stirred at room temperature for 4 . 5 h . the mixture was concentrated and the precipitate collected by filtration and washed with a little acetone . the washings and filtrate were combined , concentrated and loaded onto a silica gel biotage column which was eluted with 24 : 1 chloroform : methanol . fractions which contained the more polar component were combined and evaporated to give a cream coloured solid . this was combined with the solid isolated above and dried in vacuo to give a pale beige coloured solid ( 19 . 7 g ). this was dissolved in warm water , the ph adjusted to 2 with concentrated hydrochloric acid and the mixture extracted with ethyl acetate . the organic extract was dried ( na 2 so 4 ) and evaporated to give , after drying at 50 ° c ., the title compound as a cream coloured solid ( 18 . 081 g , 82 %): lcms retention time 3 . 88 min , m / z 507 mh + , nmr δ ( cdcl 3 ) includes 7 . 61 ( 1h , m ), 7 . 18 - 7 . 12 ( 2h , m ), 6 . 52 ( 1h , dd , j 4 , 2 hz ), 6 . 46 ( 1h , s ), 6 . 41 ( 1h , dd , j 10 , 2 hz ), 5 . 47 and 5 . 35 ( 1h , 2m ), 4 . 47 ( 1h , bd , j = 9 hz ), 3 . 37 ( 1h , m ), 1 . 55 ( 3h , s ), 1 . 21 ( 3h , s ), 1 . 06 ( 3h , d , j = 7 hz ). a stirred suspension of 6α , 9α - difluoro - 11β , 17α - dihydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid ( prepared in accordance with the procedure described in gb 2088877b ) ( 1 wt , 49 . 5 g ) in acetone ( 10 vol ) is cooled to 0 - 5 ° c . and treated with triethylamine ( 0 . 51 wt , 2 . 1 eq ), keeping the temperature below 5 ° c ., and stirred for 5 min at 0 - 5 ° c . 2 - furoyl chloride ( 0 . 65 wt , 2 . 05 eq ) is then added over a minimum of 20 min , maintaining a reaction temperature at 0 - 5 ° c . the reaction is stirred for 30 min at 0 - 5 ° c . then sampled for analysis by hplc . a solution of diethanolamine ( 1 . 02 wt , 4 eq ) in methanol ( 0 . 8 vol ) is added over ca 15 min followed by a line wash of methanol ( 0 . 2 vol ) and the reaction stirred at 0 - 5 ° c . for 1 h . the reaction is again sampled for analysis by hplc then warmed to approximately 20 ° c . and treated with water ( 1 . 1 wt ). the reaction mixture is then treated with a solution of hcl ( sg1 . 18 ( 11 . 5m ), 1 vol ) in water ( 10 vol ) over ca 20 min maintaining a reaction temperature below 25 ° c . the suspension is stirred at 20 - 23 ° c . for at least 30 minutes then filtered . the filter cake is washed with water ( 3 × 2 vol ). the product is dried in vacuo at approximately 60 ° c . overnight to give the title compound as a white solid ( 58 . 7 g , 96 . 5 %). a stirred suspension of 6α , 9α - difluoro - 11β , 17α - dihydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid ( prepared in accordance with the procedure described in gb 2088877b ) ( 1 wt , 49 . 5 g ) in acetone ( 10 vol ) is cooled to 0 - 5 ° c . and treated with triethylamine ( 0 . 51 wt , 2 . 1 eq ), keeping the temperature below 5 ° c ., and stirred for 5 min at 0 - 5 °. 2 - furoyl chloride ( 0 . 65 wt , 2 . 05 eq ) is then added over a minimum of 20 min , maintaining a reaction temperature at 0 - 5 ° c . the reaction mixture is stirred for at least 30 minutes and diluted with water ( 10 vol ) maintaining a reaction temperature in the range 0 - 5 ° c . the resultant precipitate is collected by filtration and washed sequentially with acetone / water ( 50 / 50 2 vol ) and water ( 2 × 2 vol ). the product is dried under vacuum at approximately 55 ° c . overnight to leave 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - yl s -( 2 - furanylcarbonyl ) thioanhydride as a white solid ( 70 . 8 g , 98 . 2 %) ( nmr δ ( cd 3 cn ) 0 . 99 ( 3h , d ) ( j = 7 . 3 hz ), 1 . 24 ( 3h , s ), 1 . 38 ( 1h , m ) ( j = 3 . 9 hz ), 1 . 54 ( 3h , s ), 1 . 67 ( 1h , m ), 1 . 89 ( 1h , broad d ) ( j = 15 . 2 hz ), 1 . 9 - 2 . 0 ( 1h , m ), 2 . 29 - 2 . 45 ( 3h , m ), 3 . 39 ( 1h , m ), 4 . 33 ( 1h , m ), 4 . 93 ( 1h , broad s ), 5 . 53 ( 1h , ddd ) ( j = 6 . 9 , 1 . 9 hz ; j hf = 50 . 9 hz ), 6 . 24 ( 1h , m ), 6 . 29 ( 1h , dd ) ( j = 10 . 3 , 2 . 0 hz ), 6 . 63 ( 2h , m ), 7 . 24 - 7 . 31 ( 3h , m ), 7 . 79 ( 1h , dd ) ( j =& lt ; 1 hz ), 7 . 86 ( 1h , dd ) ( j =& lt ; 1 hz )). a portion of the product ( 0 . 56 g ) is mixed with 6α , 9α - difluoro - 11β , 17α - dihydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid ( 0 . 41 g ) in a 1 : 1 molar ratio in dmf ( 10 volumes wrt total steroid input ). the reaction mixture is treated with triethylamine ( approximately 2 . 1 equivalents ) and the mixture is stirred at approximately 20 ° c . for approximately 6 hours . water ( 50 vol ) containing excess conc hcl ( 0 . 5 vol ) is added to the reaction mixture and the resultant precipitate collected by filtration . the bed is washed with water ( 2 × 5 vol ) and dried in vacuo at approximately 55 ° c . overnight to leave the title compound as a white solid ( 0 . 99 g , 102 %). a stirred suspension of 6α , 9α - difluoro - 11β , 17α - dihydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid ( prepared in accordance with the procedure described in gb 2088877b ) ( 49 . 5 g ) in methylacetate ( 500 ml ) is treated with triethylamine ( 35 ml ) maintaining a reaction temperature in the range 0 - 5 ° c . 2 - furoyl chloride ( 25 ml ) is added and the mixture stirred at 0 - 5 ° c . for 1 hour . a solution of diethanolamine ( 52 . 8 g ) in methanol ( 50 ml ) is added and the mixture stirred at 0 - 5 ° c . for at least 2 hours . dilute hydrochloric acid ( approx 1 m , 550 ml ) is added maintaining a reaction temperature below 15 ° c . and the mixture stirred at 15 ° c . the organic phase is separated and the aqueous phase is back extracted with methyl acetate ( 2 × 250 ml ). all of the organic phases are combined , washed sequentially with brine ( 5 × 250 ml ) and treated with di - isopropylethylamine ( 30 ml ). the reaction mixture is concentrated by distillation at atmospheric pressure to an approximate volume of 250 ml and cooled to 25 - 30 ° c . ( crystallisation of the desired product normally occurs during distillation / subsequent cooling ). tertiary butyl methyl ether ( tbme ) ( 500 ml ) is added , the slurry further cooled and aged at 0 - 5 ° c . for at least 10 minutes . the product is filtered off , washed with chilled tbme ( 2 × 200 ml ) and dried under vacuum at approximately 40 - 50 ° c . ( 75 . 3 g , 98 . 7 %). nmr ( cdcl 3 ) δ : 7 . 54 - 7 . 46 ( 1h , m ), 7 . 20 - 7 . 12 ( 1h , dd ), 7 . 07 - 6 . 99 ( 1h , dd ), 6 . 48 - 6 . 41 ( 2h , m ), 6 . 41 - 6 . 32 ( 1h , dd ), 5 . 51 - 5 . 28 ( 1h , dddd 2 j h - f 50 hz ), 4 . 45 - 4 . 33 ( 1h , bd ), 3 . 92 - 3 . 73 ( 3h , bm ), 3 . 27 - 3 . 14 ( 2h , q ), 2 . 64 - 2 . 12 ( 5h , m ), 1 . 88 - 1 . 71 ( 2h , m ), 1 . 58 - 1 . 15 ( 3h , s ), 1 . 50 - 1 . 38 ( 15h , m ), 1 . 32 - 1 . 23 ( 1h , m ), 1 . 23 - 1 . 15 ( 3h s ), 1 . 09 - 0 . 99 ( 3h , d ) a stirred suspension of intermediate 1 ( 30 g ) in ethylacetate ( 900 ml ) is treated with triethylamine ( 1 . 05 molar equivalents , 8 . 6 ml ) and the mixture is stirred at approximately 20 ° c . for 1 . 5 hours . the precipitate is filtered off , washed with ethylacetate ( 2 × 2 vol ) and dried in vacuo at 45 ° c . for 18 hours to give title compound as a white solid ( 28 . 8 g , 80 %). nmr ( cdcl 3 ) δ : 7 . 59 - 7 . 47 ( 1h , m ), 7 . 23 - 7 . 13 ( 1h , dd ), 7 . 08 - 6 . 99 ( 1h , d ), 6 . 54 - 6 . 42 ( 2h , m ), 6 . 42 - 6 . 32 ( 1h , dd ), 5 . 55 - 5 . 26 ( 1h , dddd 2 j h - f 50 hz ), 4 . 47 - 4 . 33 ( 1h , bd ), 3 . 88 - 3 . 70 ( 1h , bm ), 3 . 31 - 3 . 09 ( 6h , q ), 2 . 66 - 2 . 14 ( 5h , m ), 1 . 93 - 1 . 69 ( 2h , m ), 1 . 61 - 1 . 48 ( 3h , s ), 1 . 43 - 1 . 33 ( 9h , t ), 1 . 33 - 1 . 26 ( 1h , m ), 1 . 26 - 1 . 15 ( 3h s ), 1 . 11 - 0 . 97 ( 3h , d ). a suspension of intermediate 1 ( 2 . 5 g , 4 . 94 mmol ) was dissolved in anhydrous n , n - dimethylformamide ( 25 ml ) and sodium hydrogen carbonate ( 465 mg , 5 . 53 mmol ) was added . the mixture was stirred at − 20 ° c . and bromofluoromethane ( 0 . 77 ml , 6 . 37 mmol ) was added and the mixture was stirred at − 20 ° c . for 2 h . diethylamine ( 2 . 57 ml , 24 . 7 mmole ) was added and the mixture stirred at − 20 ° c . for 30 min . the mixture was added to 2m hydrochloric acid ( 93 ml ) and stirred for 30 min . water ( 300 ml ) was added and the precipitate was collected by filtration , washed with water and dried in vacuo at 50 ° c . to give a white solid which was recrystallised from acetone / water ( to yield the acetone solvate of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester ) and dried in vacuo at 50 ° c . to give the title compound ( 2 . 351 g , 88 %): lcms retention time 3 . 66 min , m / z 539 mh + , nmr δ ( cdcl 3 ) includes 7 . 60 ( 1h , m ), 7 . 18 - 7 . 11 ( 2h , m ), 6 . 52 ( 1h , dd , j = 4 . 2 hz ), 6 . 46 ( 1h , s ), 6 . 41 ( 1h , dd , j 10 , 2 hz ), 5 . 95 and 5 . 82 ( 2h dd , j 51 , 9 hz ), 5 . 48 and 5 . 35 ( 1h , 2m ), 4 . 48 ( 1h , m ), 3 . 48 ( 1h , m ), 1 . 55 ( 3h , s ), 1 . 16 ( 3h , s ), 1 . 06 ( 3h , d , j = 7 hz ). pharmacological activity was assessed in a functional in vitro assay of glucocorticoid agonist activity which is generally predictive of anti - inflammatory or anti - allergic activity in vivo . for the experiments in this section , compound of formula ( i ) was used as unsolvated form 1 . the functional assay was based on that described by k . p . ray et al ., biochem j . ( 1997 ), 328 , 707 - 715 . a549 cells stably transfected with a reporter gene containing the nf - κb responsive elements from the elam gene promoter coupled to spap ( secreted alkaline phosphatase ) were treated with test compounds at appropriate doses for 1 hour at 37 ° c . the cells were then stimulated with tumour necrosis factor ( tnf , 10 ng / ml ) for 16 hours , at which time the amount of alkaline phosphatase produced is measured by a standard colourimetric assay . dose response curves were constructed from which ec 50 values were estimated . in this test the compound of example 1 showed an ec 50 value of & lt ; 1 nm . the glucocorticoid receptor ( gr ) can function in at least two distinct mechanisms , by upregulating gene expression through the direct binding of gr to specific sequences in gene promoters , and by downregulating gene expression that is being driven by other transcription factors ( such as nfκb or ap - 1 ) through their direct interaction with gr . in a variant of the above method , to monitor these functions , two reporter plasmids have been generated and introduced separately into a549 human lung epithelial cells by transfection . the first cell line contains the firefly luciferase reporter gene under the control of a synthetic promoter that specifically responds to activation of the transcription factor nfκb when stimulated with tnfα . the second cell line contains the renilla luciferase reporter gene under the control of a synthetic promotor that comprises 3 copies of the consensus glucocorticoid response element , and which responds to direct stimulation by glucocorticoids . simultaneous measurement of transactivation and transrepression was conducted by mixing the two cell lines in a 1 : 1 ratio in 96 well plate ( 40 , 000 cells per well ) and growing overnight at 37 ° c . test compounds were dissolved in dmso , and added to the cells at a final dmso concentration of 0 . 7 %. after incubation for 1 h 0 . 5 ng / ml tnfa ( r & amp ; d systems ) was added and after a further 15 hours at 37 ° c ., the levels of firefly and renilla luciferase were measured using the packard firelite kit following the manufacturers &# 39 ; directions . dose response curves were constructed from which ec 50 values were determined . transrepression transactivation ( nfκb ) ( gr ) ed 50 ( nm ) ed 50 ( nm ) compound of 0 . 06 0 . 20 formula ( i ) metabolite ( x ) & gt ; 250 & gt ; 1000 fluticasone 0 . 07 0 . 16 propionate pharmacological activity in vivo was assessed in an ovalbumin sensitised brown norway rat eosinophilia model . this model is designed to mimic allergen induced lung eosinophilia , a major component of lung inflammation in asthma . for the experiments in this section , compound of formula ( i ) was used as unsolvated form 1 . compound ( i ) produced dose dependant inhibition of lung eosinophilia in this model after dosing as an intra - tracheal ( it ) suspension in saline 30 min prior to ovalbumin challenge . significant inhibition is achieved after a single dose of 30 μg of compound ( i ) and the response was significantly ( p = 0 . 016 ) greater than that seen with an equivalent dose of fluticasone propionate in the same study ( 69 % inhibition with compound ( i ) vs 41 % inhibition with fluticasone propionate ). in a rat model of thymus involution 3 daily it doses of 100 μg of compound ( i ) induced significantly smaller reductions in thymus weight ( p = 0 . 004 ) than an equivalent dose of fluticasone propionate in the same study ( 67 % reduction of thymus weight with compound ( i ) vs 78 % reduction with fluticasone propionate ). taken together these results indicate a superior therapeutic index for compound ( i ) compared to fluticasone propionate . incubation of compound ( i ) with rat or human hepatocytes shows the compound to be metabolised in an identical manner to fluticasone propionate with the 17 - β carboxylic acid ( x ) being the only significant metabolite produced . investigation of the rate of appearance of this metabolite on incubation of compound ( i ) with human hepatocytes ( 37 ° c ., 10 μm drug concentration , hepatocytes from 3 subjects , 0 . 2 and 0 . 7 million cells / ml ) shows compound ( i ) to be metabolised ca . 5 - fold more rapidly than fluticasone propionate :— 17 - β acid metabolite production subject cell density ( pmol / h ) number ( million cells / ml ) compound ( i ) fluticasone propionate 1 0 . 2 48 . 9 18 . 8 1 0 . 7 73 . 3 35 . 4 2 0 . 2 118 9 . 7 2 0 . 7 903 23 . 7 3 0 . 2 102 6 . 6 3 0 . 7 580 23 . 9 median metabolite production 102 - 118 pmol / h for compound ( i ) and 18 . 8 - 23 . 0 pmol / h for fluticasone propionate . compound ( i ) was dosed orally ( 0 . 1 mg / kg ) and iv ( 0 . 1 mg / kg ) to male wistar han rats and pharmacokinetic parameters determined . compound ( i ) showed negligible oral bioavailability ( 0 . 9 %) and plasma clearance of 47 . 3 ml / min / kg , approaching liver blood flow ( plasma clearance of fluticasone propionate = 45 . 2 ml / min / kg ). anaesthetised pigs ( 2 ) were dosed intra - tracheally with a homogenous mixture of compound ( i ) ( 1 mg ) and fluticasone propionate ( 1 mg ) as a dry powder blend in lactose ( 10 % w / w ). serial blood samples were taken for up to 8 h following dosing . plasma levels of compound ( i ) and fluticasone propionate were determined following extraction and analysis using lc - ms / ms methodology , the lower limits of quantitation of the methods were 10 and 20 pg / ml for compound ( i ) and fluticasone propionate respectively . using these methods compound ( i ) was quantifiable up to 2 hours after dosing and fluticasone propionate was quantifiable up to 8 hours after dosing . maximum plasma concentrations were observed for both compounds within 15 min after dosing . plasma half - life data obtained from iv dosing ( 0 . 1 mg / kg ) was used to calculate auc ( 0 - inf ) values for compound ( i ). this compensates for the plasma profile of compound ( i ) only being defined up to 2 hours after an it dose and removes any bias due to limited data between compound ( i ) and fluticasone propionate . c max and auc ( 0 - inf ) values show markedly reduced systemic exposure to compound ( i ) compared to fluticasone propionate :— auc cmax ( 0 - inf ) ( pg / ml ) ( hr · pg / ml ) pig 1 pig 2 pig 1 pig 2 compound of formula ( i ) 117 81 254 221 fluticasone propionate 277 218 455 495 the pharmacokinetic parameters for both compound ( i ) and fluticasone propionate were the same in the anaesthetised pig following intravenous administration of a mixture of the two compounds at 0 . 1 mg / kg . the clearance of these two glucocorticoids is similar is this experimental pig model . a mobile suspension of intermediate 1a ( 12 . 61 g , 19 . 8 mmol ; equivalent to 10 g of intermediate 1 ) in ethyl acetate ( 230 ml ) and water ( 50 ml ) is treated with a phase transfer catalyst ( benzyltributylammonium chloride , 10 mol %), cooled to 3 ° c . and treated with bromofluoromethane ( 1 . 10 ml , 19 . 5 mmol , 0 . 98 equivalents ), washing in with prechilled ( 0 ° c .) ethyl acetate ( etoac ) ( 20 ml ). the suspension is stirred overnight , allowing to warm to 17 ° c . the aqueous layer is separated and the organic phase is sequentially washed with 1m hcl ( 50 ml ), 1 % w / v nahco 3 solution ( 3 × 50 ml ) and water ( 2 × 50 ml ). the ethylacetate solution is distilled at atmospheric pressure until the distillate reaches a temperature of approximately 73 ° c . at which point toluene ( 150 ml ) is added . distillation is continued at atmospheric pressure until all remaining etoac has been removed ( approximate distillate temperature 103 ° c .). the resultant suspension is cooled and aged at & lt ; 10 ° c . and filtered off . the bed is washed with toluene ( 2 × 30 ml ) and the product oven dried under vacuum at 60 ° c . to constant weight to yield the title compound ( 8 . 77 g , 82 %) a suspension of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester acetone solvate ( prepared eg according to example 11 ) ( 50 . 0 g ) in acetone ( 1500 ml ) and water ( 75 ml ) was heated to reflux . the resultant mixture was clarified by hot filtration ( whatman 54 filter paper ) during which time some solid crystallised in the filtrate . further acetone ( 200 ml ) was added to the filtrate giving a bright solution at reflux . the solution was distilled at atmospheric pressure until turbidity was noted whilst at reflux ( approx 750 ml solvent collected ). toluene ( 1000 ml ) was added to the hot solution and distillation at atmospheric pressure was continued giving crystallisation at a temperature of approximately 98 ° c . distillation of solvent was continued until a reaction temperature of 105 ° c . was achieved ( approximately 945 ml solvent collected ). the mixture was cooled to ambient temperature , further cooled and aged at & lt ; 10 ° c . for 10 minutes . the product was filtered off , washed with toluene ( 150 ml ) and sucked dry . the product was dried at approximately 60 ° c . under vacuum for 16 h to leave the title compound as a dense white solid ( 37 . 8 g , 83 . 7 %). the xrpd pattern of example 1 product is shown in fig1 . the dsc and tga profiles are shown in fig3 . a suspension of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester ( prepared for example according to example 1 , first method ) ( 6 . 0 g ) in dichloromethane ( 180 ml ) was heated to reflux giving a bright solution . the solution was clarified by hot filtration ( whatman 54 filter paper ) and the solution was distilled at atmospheric pressure ( approx 100 ml solvent collected ) giving crystallisation at reflux . the mixture was held at reflux for approximately 30 minutes and slowly cooled to ambient temperature . the mixture was further cooled and aged at 10 - 20 ° c . for 2 hours . the slurry was cooled to below 10 ° c . and the product was filtered off , sucked dry and dried at approximately 60 ° c . under vacuum overnight to leave a white solid ( 4 . 34 g , 71 %). a more pure sample of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester unsolvated form 2 was obtained by a cooling crystallisation of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester ( prepared eg according to example 1 , first method ) in methanol ( 60 volumes , distilled at atmospheric pressure to approx 37 . 5 volumes ). the product was isolated by filtration and oven dried at 60 ° c . under vacuum for 16 hours to leave a white , electrostatic solid ( 4 . 34 g , 71 %). the xrpd pattern of example 2 product is shown in fig1 . a suspension of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester acetone solvate ( prepared eg according to example 11 ) ( 20 . 0 g ) in dichloromethane ( 800 ml , 40 volumes ) and water ( 10 ml , 0 . 5 volumes ) was heated to reflux giving a bright solution . the solution was clarified by hot filtration ( whatman 54 filter paper ) during which time some solid crystallised in the filtrate which was fully dissolved upon heating to reflux . the solution was distilled at atmospheric pressure ( approx 400 ml solvent collected ) and allowed to cool to ambient temperature . the mixture was further cooled and aged at & lt ; 10 ° c . for 10 minutes . the product was filtered off , sucked dry and dried at approximately 60 ° c . under vacuum overnight to leave a white solid ( 12 . 7 g , 70 %). the xrpd pattern of example 3 product is shown in fig1 and fig4 . interconversion of forms 1 , 2 and 3 of unsolvated 6α , 9α - difluoro - 17α -[( 2 - furanvicarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester slurrying a mixture of form 1 and form 2 in water at ambient temperature revealed that the components are transformed entirely to form 1 with time . xrpd results are shown in fig2 . similar results were obtained by slurrying a mixture of form 1 and form 2 in ethanol at ambient temperature . from these results it may be concluded that form 1 is the thermodynamically more stable polymorphic form out of the two forms . thermal xrpd studies on form 3 were performed as shown in fig4 . the temperature and time profile is shown in fig5 and the 5 traces shown in fig4 were obtained at the equilibration points shown in fig5 . the results indicate that form 3 is converted first to form 2 and then to form 1 as temperature is elevated . moisture sorption of forms 1 , 2 and 3 of unsolvated 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester the moisture sorption characteristics of the three forms were determined by monitoring the weight change of solid when exposed to stepwise increased and then decreased humidity . the results obtained were as follows : form 1 : uptake of 0 . 18 % w / w of moisture over the range 0 - 90 % relative humidity at 25 ° c . form 2 : uptake of 1 . 1 - 2 . 4 % w / w of moisture over the range 0 - 90 % relative humidity at 25 ° c . form 3 : uptake of 1 . 2 - 2 . 5 % w / w of moisture over the range 0 - 90 % relative humidity at 25 ° c . enthalpy of dissolution of forms 1 and 3 of unsolvated 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester enthalpies of dissolution in dmso and acetonitrile were determined at 25 ° c . the results were as follows : form these results it may be determined that the enthalpy of transition from form 3 to form 1 is approximately 5 . 1 - 6 . 7 kj / mol . on the assumption that the entropy of transition is small , since both forms are unsolvated , the enthalpy of transition may be equated with the free energy of transition . thus these data suggest that form 1 is the thermodynamically most stable form at 25 ° c . a suspension of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester ( prepared eg according to example 1 ) ( 400 mg ) in methylethylketone ( 3 . 2 ml ) is heated to reflux giving a clear solution . a portion of the solvent is distilled off at atmospheric pressure ( approx 1 ml ) and the mixture cooled to approximately 20 ° c . the crystallised product is filtered off , dried at approximately 20 ° c . under vacuum to leave the title compound as a white solid ( 310 mg , 68 %). nmr δ ( cdcl 3 ) includes the peaks described in example 1 for the parent compound and the following additional solvent peaks : 2 . 45 ( 2h , q ), 2 . 14 ( 3h , s ), 1 . 06 ( 3h , t ). a solution of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester ( prepared eg according to example 1 ) ( 150 mg ) in isopropanol ( 15 ml ) is left to slowly crystallise over a period of approximately 8 weeks . the resultant chunky crystals are isolated by filtration to leave the title compound as a white solid . nmr δ ( cdcl 3 ) includes the peaks described in example 1 for the parent compound and the following additional solvent peaks : 4 . 03 ( 1h , m ), 1 . 20 ( 6h , d ). a suspension of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester ( prepared eg according to example 1 ) ( 150 mg ) in thf ( 20 vol ) is warmed to give a clear solution . the solvent is allowed to slowly evaporate over a period of 6 days to leave title compound as a white solid . alternatively , the thf solution is added dropwise to solution of potassium bicarbonate ( 2 % w / w ) in water ( 50 vol ) and the precipitated product collected by filtration to furnish the title compound as a white solid . nmr δ ( cdcl 3 ) includes the peaks described in example 1 for the parent compound and the following additional solvent peaks : 3 . 74 ( 4h , m ), 1 . 85 ( 4h , m ). a mobile suspension of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid triethylamine salt ( prepared eg according to intermediate 1b ) ( 1 . 2 g ) in thf ( 10 ml ) is treated with a phase transfer catalyst ( tetrabutylammonium bromide , typically between 8 and 14 mol %), cooled to approximately 3 ° c . and treated with bromofluoromethane ( 0 . 98 equivalents ). the suspension is stirred for between 2 and 5 hours , allowing to warm to 17 ° c . the reaction mixture is poured into water ( 30 vol ), stirred at approximately 10 ° c . for 30 minutes and filtered off . the collected solid is washed with water ( 4 × 3 vol ) and the product oven dried under vacuum at 60 ° c . overnight to give the title compound as a white solid ( 0 . 85 g , 87 %). a mixture of intermediate 1 ( 4 . 5 g , 8 . 88 mmol ) in dmf ( 31 ml ) is treated with potassium bicarbonate ( 0 . 89 g , 8 . 88 mmol ) and the mixture is cooled to − 20 ° c . a solution of bromofluoromethane ( 0 . 95 g , 8 . 50 mmol , 0 . 98 eqv .) in dmf ( 4 . 8 ml ) at 0 ° c . is added and the mixture is stirred at − 20 ° c . for 4 hours . the mixture is then stirred at − 20 ° c . for a further 30 minutes , added to 2m hydrochloric acid ( 100 ml ) and stirred for a further 30 minutes at 0 - 5 ° c . the precipitate collected by vacuum filtration , washed with water and dried at 50 ° c . to give the title compound ( 4 . 47 g , 82 %). nmr 6 ( cd 3 od ) includes the peaks described in example 1 for the parent compound and the following additional solvent peaks : 7 . 98 ( 1h , bs ), 2 . 99 ( 3h , s ), 2 . 86 ( 3h , s ). a solution of intermediate 1 ( 530 . 1 g , 1 wt ) in dimethylformamide ( dmf ) ( 8 vol ) is treated with potassium hydrogen carbonate ( 0 . 202 wt , 1 . 02 eq ) and the mixture cooled to − 17 ± 3 ° c . with stirring . bromofluoromethane ( bfm ) ( 0 . 22 wt , 0 . 99 eq ) is then added and the reaction stirred at − 17 ± 3 ° c . for at least 2 h . the reaction mixture is then added to water ( 17 vol ) at 5 ± 3 ° c . over ca 10 min followed by a water ( 1 vol ) line wash . the suspension is stirred at 5 - 10 ° c . for at least 30 min and then filtered . the filter cake ( the dmf solvate of 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester ) is washed with water ( 4 × 4 vol ) and the product is pulled dry on the filter . the damp cake is returned to the vessel , acetone ( 5 . 75 vol ) added and heated at reflux for 2 h . the mixture is cooled to 52 ± 3 ° c . and water ( 5 . 75 vol ) added , keeping temperature at 52 ± 3 ° c . the mixture is then cooled to 20 ± 3 ° c ., filtered and dried in vacuo at 60 ± 5 ° c . overnight to give the title compound as a white solid ( 556 . 5 g , 89 %). nmr δ ( cdcl 3 ) includes the peaks described in example 1 for the parent compound and the following additional solvent peaks : 2 . 17 ( 6h , s ). dry powder composition containing 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester . unsolvated form 1 [ 0274 ] a dry powder formulation was prepared as follows : 6α , 9α - difluoro - 17α -[( 2 - 0 . 20 mg furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester , unsolvated form 1 ( prepared according to example 1 , first alternative method and micronised to a mmd of 3 μm ): milled lactose ( wherein not greater than 85 % of 12 mg particles have a mmd of 60 - 90 μm , and not less than 15 % of particles have a mmd of less than 15 μm ): a peelable blister strip containing 60 blisters each filled with a formulation as just described was prepared . [ 0276 ] an aluminium canister was filled with a formulation as follows : 6α , 9α - difluoro - 17α -[( 2 - furanylcarbonyl ) oxy ]- 250 μg 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester , unsolvated form 1 ( prepared according to example 1 , first alternative method ) and micronised to a mmd of 3 μm ): 1 , 1 , 1 , 2 - tetrafluoroethane : to 50 μl ( amounts per actuation ) in a total amount suitable for 120 actuations and the canister was fitted with a metering valve adapted to dispense 50 μl per actuation . in a total amount suitable for 120 actuations and the canister was fitted with a metering valve adapted to dispense 50 μl per actuation . [ 0278 ] a formulation for intranasal delivery was prepared as follows : 6α , 9α - difluoro - 17α -[( 2 - 10 mg furanylcarbonyl ) oxy ]- 11β - hydroxy - 16α - methyl - 3 - oxo - androsta - 1 , 4 - diene - 17β - carbothioic acid s - fluoromethyl ester unsolvated form 1 ( prepared according to example 1 , first alternative method , micronised ): polysorbate 20 0 . 8 mg sorbitan monolaurate 0 . 09 mg sodium dihydrogen phosphate dihydrate 94 mg dibasic sodium phosphate anhydrous 17 . 5 mg sodium chloride 48 mg demineralised water to 10 ml the formulation was fitted into a spraypump capable of delivering a plurality of metered doses ( valois ). throughout the specification and the claims which follow , unless the context requires otherwise , the word ‘ comprise ’, and variations such as ‘ comprises ’ and ‘ comprising ’, will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps . the patents and patent applications described in this application are herein incorporated by reference .
the present invention relates to , for example , a compound of formula useful in the manufacture of anti - inflammatory androstane derivatives .